Skip to main content
Top
Published in:

Open Access 01-06-2024 | Liver Resection | Original Article

Liver Resection Criteria for Patients with Hepatocellular Carcinoma and Multiple Tumors Based on Total Tumor Volume

Authors: Hao-Wen Shih, Yin Lai, Hao‐Chien Hung, Jin‐Chiao Lee, Yu-Chao Wang, Tsung‐Han Wu, Chen‐Fang Lee, Ting‐Jung Wu, Hong‐Shiue Chou, Kun‐Ming Chan, Wei‐Chen Lee, Chih‐Hsien Cheng

Published in: Digestive Diseases and Sciences | Issue 8/2024

Login to get access

Abstract

Background

In many Asian hepatocellular carcinoma (HCC) guidelines, resection is an option for multiple HCCs. It is difficult to compare small but multiple tumors vs. fewer large tumors in terms of the traditional tumor burden definition. We aimed to evaluate the role of liver resection for multiple HCCs and determine factors associated with survival benefits.

Methods

We reviewed 160 patients with multiple HCCs who underwent liver resection between July 2003 and December 2018. The risk factors for tumor recurrence were assessed using Cox proportional hazards modeling, and survival was analyzed using the Kaplan–Meier method.

Results

In all 160 patients, 133 (83.1%) exceeded the Milan criteria. Total tumor volume (TTV) > 275 cm3 and serum alpha-fetoprotein (AFP) level > 20 ng/mL were associated with disease-free survival. Patients beyond the Milan criteria were grouped into three risk categories: no risk (TTV ≤ 275 cm3 and AFP ≤ 20 ng/mL, n = 39), one risk (either TTV > 275 cm3 or AFP > 20 ng/mL, n = 76), and two risks (TTV > 275 cm3 and AFP > 20 ng/mL, n = 18). No-risk group had comparable disease-free survival (p = 0.269) and overall survival (p = 0.215) to patients who met the Milan criteria.

Conclusion

Patients with TTV ≤ 275 cm3 and AFP ≤ 20 ng/mL can have good outcomes even exceed the Milan criteria.
Appendix
This content is only visible if you are logged in and have the appropriate permissions.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Liver Resection Criteria for Patients with Hepatocellular Carcinoma and Multiple Tumors Based on Total Tumor Volume
Authors
Hao-Wen Shih
Yin Lai
Hao‐Chien Hung
Jin‐Chiao Lee
Yu-Chao Wang
Tsung‐Han Wu
Chen‐Fang Lee
Ting‐Jung Wu
Hong‐Shiue Chou
Kun‐Ming Chan
Wei‐Chen Lee
Chih‐Hsien Cheng
Publication date
01-06-2024
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2024
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-024-08500-y

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more

ADA 2025

Unlock your free and exclusive access to the latest news from the American Diabetes Association’s 85th Scientific Sessions.

Read more